Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Tactile Systems Technology, Inc.

Rank #11Capital ReturnWatchlistCompare with other stocks

TCMD · Nasdaq · Healthcare

Tactile Systems Technology, Inc. (TCMD) — Rank #11 by gross profitability (GP/assets 0.89) · ROE 8.5% · Piotroski F-Score N/A.

As-of 2026-10-30 · CIK 0001027838 · all metrics point-in-time as of the filing date.

About

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States.

Show more

It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc.

was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Industry
Medical Devices
Sector
Healthcare
State
MN
Filer Category
Accelerated filer
Fiscal Year End
December 31

Company Snapshot

P/E and reverse DCF are the primary valuation lenses at this stage.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

1,086

Industry

Medical Devices

Exchange

Nasdaq

11/11

Flags passed

TCMD passes 11/11 quality flags

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Revenue growth accelerating · Operating leverage expanding · Sequential beat (rev + EPS)

No data Balance sheet — not counted as a pass.

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.89
Return on equity
8.5%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.25
Current ratio
4.12×
Net cash
$69.85M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
2.5%

Growth

2/2 pass
Revenue growth
12.5%
Piotroski F-Score
N/A
Share dilution
-3.5%

FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 95th percentile of 20 SIC 3841 peers

Gross profitability (GP / assets)

0.89

Primary signal (Novy-Marx).

95th pctl of 20 SIC 3841 peers

Return on equity

8.5%

Gross margin

75.9%

100th pctl of 20 SIC 3841 peers

Revenue growth (YoY)

12.5%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

10.1%

Revenue CAGR (5Y)

12.0%

Earnings CAGR (3Y)

—

FCF CAGR (3Y)

127.6%

Cash Flow Health

Is the cash real?

No warning flags · FCF 112% above net income

Free cash flow

$40.43M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

111.8%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

2.5%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

No warning flags · net cash $69.85M

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.25

2nd of 19 SIC 3841 peers (best = lowest)

Current ratio

4.12×

74th pctl of 20 SIC 3841 peers

Quick ratio

2.95×

Net cash

$69.85M

Cash & equivalents minus total debt.

Piotroski F-Score

N/A

Only 8/9 components determinable.

Valuation

Is the price reasonable?

No warning flags

Capital allocation quality

Composite score

4.0 / 5

Strong
Share count trend(net buybacks)
-3.5%4/5 Strong
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory(deleveraging)
5.9%5/5 Strong

Lifecycle Phase History

20202025
Startup
Op. Leverage
Value
Capital Return

Price History

TCMD-47.2% · -12.0% CAGRSPY+82.9% · +12.8% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports